hydralazine has been researched along with Nephrosclerosis in 10 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Nephrosclerosis: Hardening of the KIDNEY due to infiltration by fibrous connective tissue (FIBROSIS), usually caused by renovascular diseases or chronic HYPERTENSION. Nephrosclerosis leads to renal ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " After 4 weeks of DOCA-salt hypertension, rats were either killed (n = 6), or treated with a non-hypotensive dose of spironolactone (n = 7) or triple therapy (hydrochlorothiazide, reserpine and hydralazine, n = 8) to normalize blood pressure or with vehicle (n = 19) for two further weeks." | 3.74 | Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. ( Cordasic, N; Hartner, A; Hilgers, KF; Klanke, B; Schmieder, RE; Veelken, R, 2008) |
| " Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo." | 3.71 | Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Griffin, KA | 1 |
| Polichnowski, A | 1 |
| Litbarg, N | 1 |
| Picken, M | 1 |
| Venkatachalam, MA | 1 |
| Bidani, AK | 1 |
| Klanke, B | 2 |
| Cordasic, N | 1 |
| Hartner, A | 2 |
| Schmieder, RE | 1 |
| Veelken, R | 1 |
| Hilgers, KF | 2 |
| LONGARETTI, A | 1 |
| BELSITO, F | 1 |
| Herrera, J | 1 |
| Chávez, M | 1 |
| Marín, C | 1 |
| Westhoff, JH | 1 |
| Steinbach, MP | 1 |
| Amann, K | 1 |
| Melk, A | 1 |
| Vaziri, ND | 1 |
| Nakaya, H | 1 |
| Sasamura, H | 1 |
| Hayashi, M | 1 |
| Saruta, T | 1 |
| Pettinger, WA | 1 |
| Mitchell, HC | 1 |
| Lee, HC | 1 |
| Redman, HC | 1 |
| Fillastre, JP | 1 |
| Malandain, M | 1 |
| Gray, H | 1 |
| Dubois, D | 1 |
| Mattern, WD | 1 |
| Sommers, SC | 1 |
| Kassirer, JP | 1 |
1 review available for hydralazine and Nephrosclerosis
| Article | Year |
|---|---|
Malignant or accelerated hypertension.
Topics: Blood Coagulation Disorders; Brain Diseases; Diazoxide; Glomerulosclerosis, Focal Segmental; Humans; | 1984 |
1 trial available for hydralazine and Nephrosclerosis
| Article | Year |
|---|---|
Pseudo renal artery stenosis (PRAS) syndrome.
Topics: Angiography; Blood Pressure; Body Weight; Creatinine; Double-Blind Method; Enalapril; Humans; Hydral | 1989 |
8 other studies available for hydralazine and Nephrosclerosis
| Article | Year |
|---|---|
Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Drug Therapy, | 2014 |
Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dise | 2008 |
[CLINICAL RESEARCH WITH A COMPOUND HYPOTENSIVE PREPARATION (MEBUTAMATE + 1-4 DIHYDRAZINOPHTHALAZINE + DIHYDROCHLOROTHIAZIDE + POTASSIUM)].
Topics: Antihypertensive Agents; Arteriosclerosis; Carbamates; Humans; Hydralazine; Hydrochlorothiazide; Hyp | 1963 |
Transient improvement of hypertension-induced chronic renal failure with mycophenolate mofetil treatment.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Captopril; | 2006 |
Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Ag | 2008 |
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten | 2001 |
[Treatment of malignant nephroangiosclerosis with diazoxide].
Topics: Diazoxide; Glomerular Filtration Rate; Humans; Hydralazine; Hypertension, Malignant; Injections, Int | 1972 |
Oliguric acute renal failure in malignant hypertension.
Topics: Acute Kidney Injury; Adult; Anuria; Blood Urea Nitrogen; Diagnosis, Differential; Female; Glomerulon | 1972 |